SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2001-11-0078. This Article Full Text Full Text (PDF) All Versions of this Article: 2001-11-0078v1 99/11/4225    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Castelli, J. C. Articles by Levy, J. A. Search for Related Content PubMed PubMed Citation Articles by Castelli, J. C. Articles by Levy, J. A. Related Collections Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 June 2002, Vol. 99, No. 11, pp. 4225-4227 BRIEF REPORT Relationship of CD8+ T cell noncytotoxic anti-HIV response to CD4+ T cell number in untreated asymptomatic HIV-infected individuals JoAnn C. Castelli, Steven G. Deeks, Stephen Shiboski, and Jay A. Levy From the Department of Medicine and Department of Biostatistics, University of California, San Francisco. During chronic HIV infection, asymptomatic individuals demonstrate a strong CD8+ cell noncytotoxic antiviral response (CNAR). With the onset of symptoms or reduction in CD4+ cell counts, CNAR decreases. Presently, it is recommended that infected individuals receive antiretroviral therapy if CD4+ cell counts fall below 350 cells/µL. To determine whether CNAR lends support to this recommendation for initiation of antiretroviral treatment, we examined CNAR in 20 healthy, untreated, HIV-infected men exhibiting a range of CD4+ cell numbers. Our results indicate that the asymptomatic untreated HIV-infected individuals with less than 300 CD4+ cells/µL had a significantly lower CNAR than those with higher CD4+ cell counts. These data on CNAR in untreated, healthy, HIV-infected individuals support the current recommendation for when to initiate antiretroviral therapy. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: V. Dioszeghy, K. Benlhassan-Chahour, B. Delache, N. Dereuddre-Bosquet, C. Aubenque, G. Gras, R. Le Grand, and B. Vaslin Changes in Soluble Factor-Mediated CD8+ Cell-Derived Antiviral Activity in Cynomolgus Macaques Infected with Simian Immunodeficiency Virus SIVmac251: Relationship to Biological Markers of Progression J. Virol., January 1, 2006; 80(1): 236 - 245. [Abstract] [Full Text] [PDF] J. Castelli, E. K. Thomas, M. Gilliet, Y.-J. Liu, and J. A. Levy Mature dendritic cells can enhance CD8+ cell noncytotoxic anti-HIV responses: the role of IL-15 Blood, April 1, 2004; 103(7): 2699 - 2704. [Abstract] [Full Text] [PDF] C. E. Mackewicz, C. S. Craik, and J. A. Levy The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors PNAS, March 18, 2003; 100(6): 3433 - 3438. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020